ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MED Intelligent Ultrasound Group Plc

14.50
0.00 (0.00%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Intelligent Ultrasound Group Plc LSE:MED London Ordinary Share GB00BN791Q39 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.50 14.00 15.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Medaphor Group PLC Investor presentation

07/02/2018 7:00am

RNS Non-Regulatory


TIDMMED

Medaphor Group PLC

07 February 2018

MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

Investor presentation

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that it will be presenting at the Shares and AJ Bell Spotlight Evening in London on Tuesday 13 February 2018.

The Shares and AJ Bell Investor evening provides an opportunity for Directors to make a presentation and talk about their company business plans for 2018 direct to existing and potential investors.

The event will commence at 6pm at Novotel Tower Bridge, London, EC3N 2NR. At the event CEO Stuart Gall will deliver a presentation detailing the Company's strategy following the recent acquisition of Intelligent Ultrasound Limited, along with an overview of the Company, where it is currently positioned and their plans for the future.

If you are interested in attending the event and would like information on how to register please contact Walbrook PR at medaphor@walbrookpr.com

The presentation will contain no new material information and is available on the Company's website: http://investors.medaphor.com/

Enquiries:

 
 MedaPhor Group plc                             www.medaphor.com 
 Stuart Gall, CEO                            Tel: +44 (0)29 2075 
  Nicholas Sleep, CTO                                       6534 
 
 Cenkos Securities                           Tel: +44 (0)20 7397 
                                                            8900 
 Camilla Hume/Bobbie Hilliam 
  (Nominated Advisor) 
 Michael Johnson / Julian 
  Morse (Corporate Broking) 
 
 Walbrook PR                         Tel: +44 (0)20 7933 8780 or 
                                         medaphor@walbrookpr.com 
 Paul McManus / Anna             Mob: +44 (0)7980 541 893 / Mob: 
  Dunphy                                     +44 (0)7876 741 001 
 
 

About MedaPhor (www.medaphor.com)

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops advanced hi-fidelity haptic and manikin based training simulators, clinical image analysis software tools, augmented reality based needle guidance software and artificial intelligence based automated scanning software for all medical practitioners.

Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:

Ultrasound Simulation and Training

Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer(TM) OBGYN and General Medical simulator training platform, the HeartWorks(TM) echocardiography simulator platform and the BodyWorks Eve(TM) Point-of-Care simulator platform (launching January 2018). Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

Intelligent Ultrasound

Focuses on developing augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. ScanNav(TM) uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide(TM) aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXAKELAPEFF

(END) Dow Jones Newswires

February 07, 2018 02:00 ET (07:00 GMT)

1 Year Intelligent Ultrasound Chart

1 Year Intelligent Ultrasound Chart

1 Month Intelligent Ultrasound Chart

1 Month Intelligent Ultrasound Chart

Your Recent History

Delayed Upgrade Clock